FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Enforcement of universal screenings would easily prevent sickness, expenses and death but enforcement isn’t easy.

When the liver is badly scarred by cirrhosis, the consequences are not just digestive. It can creep up and affect your brain ...

Serious infections significantly increase the mortality risk among adults with chronic liver disease, including those without cirrhosis.

GAAP loss per share of ($0.12) in Q2 2025 beat expectations, driven by a sharp drop in research and development costs. No revenue reported, reflecting ongoing clinical-stage operations and focus on ...

Pooled data show that no or shorter antibiotic prophylaxis for upper GI bleeding in cirrhosis is very likely noninferior to longer courses for all-cause mortality, challenging long-standing advice.

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...

Cirrhosis, or advanced and largely irreversible scarring of the liver, damages healthy tissue and prevents the organ from working normally.

Liver cirrhosis can cause ascites in the liver due to the accumulation of fluid. Learn more here about ascites and liver cirrhosis here.